NUVL
Nuvalent IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$8.01B
P/E Ratio
—
EPS
$-5.85
Beta
1.31
52W High
$113.02
52W Low
$63.55
50-Day MA
$102.02
200-Day MA
$94.72
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Nuvalent Inc
Nuvalent Inc. is a pioneering clinical-stage biopharmaceutical company specializing in the development of targeted therapies for cancer patients with genetically defined diseases. Utilizing its proprietary drug discovery platform, Nuvalent aims to deliver innovative solutions that specifically address genetic mutations implicated in tumor growth, thereby enhancing patient outcomes while reducing side effects. With a robust pipeline of highly selective therapies, the company is strategically positioned to capitalize on emerging opportunities within the precision oncology market, emphasizing its commitment to transforming cancer treatment and significantly improving patient care in the oncology landscape.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | -36.70% |
| Return on Assets | -20.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $15.96 |
| Price-to-Book | 6.42 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -22.26 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $73.18M |
| Float | $48.68M |
| % Insiders | 2.75% |
| % Institutions | 111.51% |
Historical Volatility
HV 10-Day
32.65%
HV 20-Day
30.01%
HV 30-Day
32.12%
HV 60-Day
30.66%
HV Rank
13.9%
Volatility is currently expanding
Analyst Ratings
Consensus ($142.37 target)
4
Strong Buy15
BuyData last updated: 4/29/2026